bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure from Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Authors: Xu Jianming , Li Jie , Bai Chunmei , Xu Nong , Zhou Zhiwei , Li Zhiping , Zhou Caicun , Jia Ru , Lu Ming , Cheng Yuejuan , Mao Chenyu , Wang Wei , Cheng Ke , Su Chunxia , Hua Ye , Qi Chuan , Li Jing , Li Ke , Sun Qiaoling , Ren Yongxin , Su Weiguo
Published: April 2023

Supplementary Figure
Table S4 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Oligonucleotide sequences to identify targeted colonies after transfection
Supplementary Methods from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Supplementary Methods
Figure S3 from Adjuvant Treatment for POLE Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Authors: Van Gool Inge C. , Rayner Emily , Osse Elisabeth M. , Nout Remi A. , Creutzberg Carien L. , Tomlinson Ian P.M. , Church David N. , Smit Vincent T.H.B.M. , de Wind Niels , Bosse Tjalling , Drost Mark
Published: April 2023

Sensitivity to nucleoside analogs cytarabine and fludarabine in Pole S297F-mutant and Pole-wild-type cell lines
Supplementary Tables 1-2 from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Authors: Rapp Carmen , Dettling Steffen , Liu Fang , Ull Anna Theresa , Warta Rolf , Jungk Christine , Roesch Saskia , Mock Andreas , Sahm Felix , Schmidt Melissa , Jungwirth Gerhard , Zweckberger Klaus , Lamszus Katrin , Gousias Konstaninos , Kessler Almuth F. , Grabe Niels , Loehr Mario , Ketter Ralf , Urbschat Steffi , Senft Christian , Westphal Manfred , Abdollahi Amir , Debus Juergen , von Deimling Andreas , Unterberg Andreas , Simon Matthias , Herold-Mende Christel C.
Published: April 2023

Suppl. Table S1: Impact of cytotoxic T-cells on patient survival; Suppl. Table S2: Impact of PD-1-expressing cytotoxic T-cells on patient survival
Supplemental Fig S3 from STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers
Authors: Moreira Dayson , Adamus Tomasz , Zhao Xingli , Su Yu-Lin , Zhang Zhuoran , White Seok Voon , Swiderski Piotr , Lu Xin , DePinho Ronald A. , Pal Sumanta K. , Kortylewski Marcin
Published: April 2023

Different inhibitors of endocytosis
Supplementary Figure Legends from Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Authors: Rapp Carmen , Dettling Steffen , Liu Fang , Ull Anna Theresa , Warta Rolf , Jungk Christine , Roesch Saskia , Mock Andreas , Sahm Felix , Schmidt Melissa , Jungwirth Gerhard , Zweckberger Klaus , Lamszus Katrin , Gousias Konstaninos , Kessler Almuth F. , Grabe Niels , Loehr Mario , Ketter Ralf , Urbschat Steffi , Senft Christian , Westphal Manfred , Abdollahi Amir , Debus Juergen , von Deimling Andreas , Unterberg Andreas , Simon Matthias , Herold-Mende Christel C.
Published: April 2023

Supplementary Figure Legends
Supplemental Table 1 from Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer
Authors: Effenberger Katharina E. , Schroeder Cornelia , Hanssen Annkathrin , Wolter Stefan , Eulenburg Christine , Tachezy Michael , Gebauer Florian , Izbicki Jacob R. , Pantel Klaus , Bockhorn Maximilian
Published: April 2023

Supplements Table 1. Multivariate analyses of progression-free survival and overall survival (n=57) of chemo-receiving patients.
Supplement from Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non–Small Cell Lung Carcinoma (NSCLC)
Authors: Frank Rieke , Scheffler Matthias , Merkelbach-Bruse Sabine , Ihle Michaela A. , Kron Anna , Rauer Michael , Ueckeroth Frank , König Katharina , Michels Sebastian , Fischer Rieke , Eisert Anna , Fassunke Jana , Heydt Carina , Serke Monika , Ko Yon-Dschun , Gerigk Ulrich , Geist Thomas , Kaminsky Britta , Heukamp Lukas C. , Clement-Ziza Mathieu , Büttner Reinhard , Wolf Jürgen
Published: April 2023

Supplemental Table 1-7 Supplemental Table 1: Diagnostic panels used for Next-generation sequencing (NGS) Supplemental Table 2: KEAP1 mutations Supplemental Table 3: NFE2L2 mutations Supplemental Table 4: Co-aberrations of KEAP1 Supplemental Table 5: Co-aberrations of NFE2L2 Supplemental Table 6: Distribution on FISH finding depending on histology Supplemental Table 7: Therapeutic outcome of patients receiving systemic therapy.
FigureS6 from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

Supplement FigureS6
Video 2 from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental Video 2. In vitro visualization of the dynamics of CD20-TCB (white) during the interaction between CD8+ T-cells (green) and tumor cells (blue).
FigureS4 from Auranofin Protects Intestine against Radiation Injury by Modulating p53/p21 Pathway and Radiosensitizes Human Colon Tumor
Authors: Nag Dhrubajyoti , Bhanja Payel , Riha Randal , Sanchez-Guerrero Giselle , Kimler Bruce F. , Tsue Terance T. , Lominska Chris , Saha Subhrajit
Published: April 2023

Supplement FigureS4
Supplemental methods from CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Authors: Bacac Marina , Colombetti Sara , Herter Sylvia , Sam Johannes , Perro Mario , Chen Stanford , Bianchi Roberta , Richard Marine , Schoenle Anne , Nicolini Valeria , Diggelmann Sarah , Limani Florian , Schlenker Ramona , Hüsser Tamara , Richter Wolfgang , Bray-French Katharine , Hinton Heather , Giusti Anna Maria , Freimoser-Grundschober Anne , Lariviere Laurent , Neumann Christiane , Klein Christian , Umaña Pablo
Published: April 2023

Supplemental materials and methods
Supplementary Information from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Information
Figure S6 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S6
7 Supplementary Tables from Krüppel-like Factor 4 Suppresses Serine/Threonine Kinase 33 Activation and Metastasis of Gastric Cancer through Reversing Epithelial–Mesenchymal Transition
Authors: Kong Fanyang , Sun Tao , Kong Xiangyu , Xie Dacheng , Li Zhaoshen , Xie Keping
Published: April 2023

7 Supplementary Tables: Supplementary Table S1. Clinicopathologic characteristics of the 625 GC patients from whom the TMA specimens were obtained Supplementary Table S2. Clinicopathologic characteristics of the 45 GC patients from whom the TMA specimens were obtained Supplementary Table S3. The sequences of the gene-specific primers used in real-time PCR analysis, vector constructs, and ChIP analysis Table S4. Expression of STK33 in Normal Mucosa, Intraepithelial Neoplasia and Gastric Cancer Table S5. Relation between STK33 Expression and Clinicopathological Parameters in Patients with Gastric Cancer Table S6. Univariate Cox Regression Analysis of Factors Associated With Overall Survival in Gastric Cancer Patients Table S7. Multivariate Cox Regression Analysis Of Factors Associated With Overall Survival in Gastric Cancer Patients
Figure S2 from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46
Authors: Liu Yen-Nien , Niu Shaoxi , Chen Wei-Yu , Zhang Qingfu , Tao Yulei , Chen Wei-Hao , Jiang Kuo-Ching , Chen Xufeng , Shi Huaiyin , Liu Aijun , Li Jinhang , Li Yanjing , Lee Yi-Chao , Zhang Xu , Huang Jiaoti
Published: April 2023

Supplementary Figure S2
Supplementary Figures from Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial
Authors: Di Cosimo Serena , Appierto Valentina , Pizzamiglio Sara , Tiberio Paola , Iorio Marilena V. , Hilbers Florentine , de Azambuja Evandro , de la Peña Lorena , Izquierdo Miguel , Huober Jens , Baselga José , Piccart Martine , de Braud Filippo G. , Apolone Giovanni , Verderio Paolo , Daidone Maria Grazia
Published: April 2023

Suppl figures without legends modified on feb 20th
Table S5 from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Whole-exome sequencing mutations variant allele frequencies used to calculate cancer cell fractions
Supplementary Materials from Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression
Authors: Keysar Stephen B. , Eagles Justin R. , Miller Bettina , Jackson Brian C. , Chowdhury Farshad N. , Reisinger Julie , Chimed Tugs-Saikhan , Le Phuong N. , Morton John J. , Somerset Hilary L. , Varella-Garcia Marileila , Tan Aik-Choon , Song John I. , Bowles Daniel W. , Reyland Mary E. , Jimeno Antonio
Published: April 2023

Supplementary Methods, References, Figure Legends, and Tables.
Table S1 from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Clinical information
Supplementary Material and Methods from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Supplementary Material and Methods Figure S1. Proportion of clonal and subclonal variants identified by whole exome sequencing. Figure S2. Mutation cancer cell fractions from whole-exome sequencing. Figure S4. Bootstrap values for targeted sequencing phylogenetic trees. Figure S5. Phylogenetic trees reconstructed from WES data. Figure S6. Phylogenetic trees reconstructed from TES data using only clonal mutations in each sample (CCF>80%). Figure S7. Measure of phylogenetic divergence.
Supplementary Figure 8 from The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer
Authors: Barry Peter , Vatsiou Alexandra , Spiteri Inmaculada , Nichol Daniel , Cresswell George D. , Acar Ahmet , Trahearn Nicholas , Hrebien Sarah , Garcia-Murillas Isaac , Chkhaidze Kate , Ermini Luca , Huntingford Ian Said , Cottom Hannah , Zabaglo Lila , Koelble Konrad , Khalique Saira , Rusby Jennifer E. , Muscara Francesca , Dowsett Mitch , Maley Carlo C. , Natrajan Rachael , Yuan Yinyin , Schiavon Gaia , Turner Nicholas , Sottoriva Andrea
Published: April 2023

Figure S8. CCF comparisons between multiple tumour samples.
Appendix tables from Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non–Small Cell Lung Cancer: A Phase Ib Study
Authors: Kim Edward S. , Kelly Karen , Paz-Ares Luis G. , Garrido Pilar , Jalal Shadia , Mahadevan Daruka , Gutierrez Martin , Provencio Mariano , Schaefer Eric , Shaheen Monte , Johnston Erica L. , Turner P. Kellie , Kambhampati Siva Rama Prasad , Beckmann Richard , Hossain Anwar , John William J. , Goldman Jonathan W.
Published: April 2023

Second part of the appendix
Supplementary Tables from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Authors: Wu Hong-Wei , Sheard Michael A. , Malvar Jemily , Fernandez G. Esteban , DeClerck Yves A. , Blavier Laurence , Shimada Hiroyuki , Theuer Charles P. , Sposto Richard , Seeger Robert C.
Published: April 2023

Supplementary Tables
Supplementary Figure S2 from Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas)
Authors: Sanfilippo Roberta , Jones Robin L. , Blay Jean-Yves , Le Cesne Axel , Provenzano Salvatore , Antoniou Georgios , Mir Olivier , Fucà Giovanni , Fumagalli Elena , Bertulli Rossella , Stacchiotti Silvia , Brahmi Mehdi , Grosso Federica , Dufresne Armelle , Hindi Nadia , Sbaraglia Marta , Gronchi Alessandro , Collini Paola , Dei Tos Angelo P. , Casali Paolo G.
Published: April 2023

Hepatic partial RECIST response to sirolimus as a first-line therapy in a man with visceral PEComa. Panel A shows the baseline CT scan; panel B shows the partial RECIST response after 2 months of treatment. Red arrows indicate a liver metastasis.
Supplementary Table S1 from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Supplementary Table S1. Overall survival in low- and high-expression cohorts.
Supplementary Information_clean version from Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling
Authors: González-González Adrián , Muñoz-Muela Esperanza , Marchal Juan A. , Cara Francisca E. , Molina Maria P. , Cruz-Lozano Marina , Jiménez Gema , Verma Akanksha , Ramírez Alberto , Qian Wei , Chen Wen , Kozielski Anthony J. , Elemento Olivier , Martín-Salvago María D. , Luque Rafael J. , Rosa-Garrido Carmen , Landeira David , Quintana-Romero María , Rosato Roberto R. , García Maria A. , Ramirez-Tortosa Cesar L. , Kim Hanna , Rodriguez-Aguayo Cristian , Lopez-Berestein Gabriel , Sood Anil K. , Lorente Jose A. , Sánchez-Rovira Pedro , Chang Jenny C. , Granados-Principal Sergio
Published: April 2023

Non-tracked version of the supplementary information document that includes supplementary materials and methods, supplementary references and supplementary figure legends
Supplementary Figure 1 from Inhibition of EphB4–Ephrin-B2 Signaling Enhances Response to Cetuximab–Radiation Therapy in Head and Neck Cancers
Authors: Bhatia Shilpa , Sharma Jaspreet , Bukkapatnam Sanjana , Oweida Ayman , Lennon Shelby , Phan Andy , Milner Dallin , Uyanga Nomin , Jimeno Antonio , Raben David , Somerset Hilary , Heasley Lynn , Karam Sana D.
Published: April 2023

Levels of EGFR expression in HNSCC PDX tumors
Table S2 from Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non–Small Cell Lung Cancer
Authors: Yu Hao , Wu Huanmei , Wang Weili , Jolly Shruti , Jin Jian-Yue , Hu Chen , Kong Feng-Ming (Spring)
Published: April 2023

patients' clinical and cytokines data
Figure S5 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

Effects of APOBEC3B and UNG expression on the prognosis of HCC patients in different cohorts
Figure S1 from Genetic Polymorphisms Predisposing the Interleukin 6–Induced APOBEC3B-UNG Imbalance Increase HCC Risk via Promoting the Generation of APOBEC-Signature HBV Mutations
Authors: Liu Wenbin , Wu Jianfeng , Yang Fan , Ma Longteng , Ni Chong , Hou Xiaomei , Wang Ling , Xu Aijing , Song Jiahui , Deng Yang , Xian Linfeng , Li Zixiong , Wang Shuo , Chen Xi , Yin Jianhua , Han Xue , Li Chengzhong , Zhao Jun , Cao Guangwen
Published: April 2023

The locations and linkage disequilibrium of APOBEC3B single nucleotide polymorphisms
Figure S8 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S8 shows IGF1R expression on MDA-MB-436 cells targeted by IGF1R siRNA
Figure S4 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

T cells numbers in brain hemisphere with untreated tumor. Tumors were implanted and treated as depicted in Fig. 2A. Three days after the last viral injection, brain-infiltrating lymphocytes from brain hemispheres with implanted tumor (4 to 5 mice/group) were analyzed with flow cytometry and the indicated cell populations were quantified as cell numbers from one hemisphere. Values represent the mean {plus minus} standard deviation (n = 3). * P < 0.05, 2-tailed Student t test. D24-RGDOX: Delta-24-RGDOX.
Figure S3 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

A, Quantification of the tumor bioluminescence in the mice from the indicated treatment groups. D24-RGDOX: Delta-24-RGDOX. B, Waterfall plots showing tumor burden change from baseline in mice of indicated treatment groups base on the bioluminescence from the tumor. Baseline time point: Day 8 for s.c. tumor, Day 15 for i.c. tumor. Evaluation time point: Day 57 or the last time point before euthanasia.
Figure S4 from Metastatic Breast Carcinoma–Associated Fibroblasts Have Enhanced Protumorigenic Properties Related to Increased IGF2 Expression
Authors: Gui Yirui , Aguilar-Mahecha Adriana , Krzemien Urszula , Hosein Abdel , Buchanan Marguerite , Lafleur Josiane , Pollak Michael , Ferrario Cristiano , Basik Mark
Published: April 2023

Figure S4 shows the top differentially regulated genes between mCAFs vs pCAFs
Figure S1 from Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Authors: Jiang Hong , Shin Dong Ho , Nguyen Teresa T. , Fueyo Juan , Fan Xuejun , Henry Verlene , Carrillo Caroline C. , Yi Yanhua , Alonso Marta M. , Collier Tiara L. , Yuan Ying , Lang Frederick F. , Gomez-Manzano Candelaria
Published: April 2023

Characterization of Delta-24-RGDOX in melanoma cells. A, Expression of mOXO40L by Delta-24-RGDOX in human A375 and mouse B16F10 Red-FLuc melanoma cells. Cells were infected with Delta-24-RGD or Delta-24-RGDOX at the indicated doses. After 48 hours, the cells were harvested, and mOX40L expression and cell death (cells with broken membrane stained with 8 Î¼M ethidium homodimer-1) were analyzed with flow cytometry. Representative dot plots for each analysis are shown. The numbers at the lower right corners indicate the percentages of live cells expressing mOX40L on their cell membrane. B, Expression of mOXO40L by Delta-24-RGDOX in B16F10 cell line and it's subclones. Cells were infected with Delta-24-RGDOX at 30 pfu/cell. After 48 hours, the cells were analyzed as in A. C, Expression of mOX40L on tumor cells from virus-treated tumors. S.c. melanomas derived from B16F10-EGFP cells were injected with D24-RGDOX nine days after tumor implantation. Three days later, tumors (3 mice per group) were harvested, and the cells were dissociated and stained with anti-mOX40L-APC. The stained cells were analyzed using flow cytometry. Tumor cells were gated for EGFP+. D, Replication of Delta-24-RGDOX in indicated cells. Cells were seeded at 5 Ã- 104 cells per well in 12-well plates and infected with the virus at 10 PFU per cell. Forty-eight hours after infection, the titers of the infectious viral progenies in the whole culture were determined using the Adeno-X-Rapid Titer Kit (Clontech) according to the manufacturer's instructions. Final viral titers were determined as PFU per milliliter. E, B16F10 Red-FLuc cells were infected with D24-RGDOX at 100 PFU/cell. Cells were harvested after 72 hours and cell lysis (cell death) was monitored with ethidium homodimer-1 staining and analyzed with flow cytometry. Values represent the mean {plus minus} standard deviation (n = 3). * P < 0.0005, 2-tailed Student t test. D24-RGD: Delta-24-RGD; D24-RGDOX: Delta-24-RGDOX.
Supplementary table 4 from Predicted Prognosis of Patients with Pancreatic Cancer by Machine Learning
Authors: Yokoyama Seiya , Hamada Taiji , Higashi Michiyo , Matsuo Kei , Maemura Kosei , Kurahara Hiroshi , Horinouchi Michiko , Hiraki Tsubasa , Sugimoto Tomoyuki , Akahane Toshiaki , Yonezawa Suguru , Kornmann Marko , Batra Surinder K. , Hollingsworth Michael A. , Tanimoto Akihide
Published: April 2023

Comparison of feature between training and test cohort.
Supplementary Figure 3 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Authors: Marzi Laetitia , Szabova Ludmila , Gordon Melanie , Weaver Ohler Zoe , Sharan Shyam K. , Beshiri Michael L. , Etemadi Moudjib , Murai Junko , Kelly Kathleen , Pommier Yves
Published: April 2023

LMP776 is synergistic with talazoparib in BRCA1-/- cells. Cell viability curves of talazoparib in DT40 WT (blue symbols and curves) and BRCA1-/- cells (red) with the indicated concentrations of LMP776. Open symbols and dashed lines correspond to talazoparib alone.
Supplementary Figure 1 from The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Authors: Marzi Laetitia , Szabova Ludmila , Gordon Melanie , Weaver Ohler Zoe , Sharan Shyam K. , Beshiri Michael L. , Etemadi Moudjib , Murai Junko , Kelly Kathleen , Pommier Yves
Published: April 2023

CellMinerCDB snapshots (http://discover.nci.nih.gov/cellminercdb) demonstrating the correlations between the activity of the three clinical indenoisoquinolines and SLFN11 expression in the NCI-60 (A-C) and in the GDSC (MGH-Sanger) panels of non-isogenic cancer cell lines. Each dot represents a cell line [59 cell lines are shown for the NCI-60 (A-C) and 712 cell lines are included in the GDSC plot (D). LMP compounds are listed by their NSC numbers in the NCI-60 panels A-C (LMP400 = NSC724998; LMP744 = NSC706744 and LMP776 = NSC725776). LMP744 a is also referred as MJ-III-65 in the GDSC (MGH-Sanger) database.
Supplementary Table S1 from Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
Authors: de Jonge Marthe M. , Ritterhouse Lauren L. , de Kroon Cornelis D. , Vreeswijk Maaike P.G. , Segal Jeremy P. , Puranik Rutika , Hollema Harry , Rookus Matti A. , van Asperen Christi J. , van Leeuwen Flora E. , Smit Vincent T.H.B.M. , Howitt Brooke E. , Bosse Tjalling
Published: April 2023

Clinicopathologic characteristics of the complete cohort
Supplementary Tables from High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden
Authors: Benayed Ryma , Offin Michael , Mullaney Kerry , Sukhadia Purvil , Rios Kelly , Desmeules Patrice , Ptashkin Ryan , Won Helen , Chang Jason , Halpenny Darragh , Schram Alison M. , Rudin Charles M. , Hyman David M. , Arcila Maria E. , Berger Michael F. , Zehir Ahmet , Kris Mark G. , Drilon Alexander , Ladanyi Marc
Published: April 2023

Supplementary Tables 1-6
Supplementary Data from CD47-Targeted Near-Infrared Photoimmunotherapy for Human Bladder Cancer
Authors: Kiss Bernhard , van den Berg Nynke S. , Ertsey Robert , McKenna Kelly , Mach Kathleen E. , Zhang Chiyuan Amy , Volkmer Jens-Peter , Weissman Irving L. , Rosenthal Eben L. , Liao Joseph C.
Published: April 2023

Supplementary methods and figures
Supplementary Figure Legends from Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Authors: Clark Amy S. , McAndrew Nicholas P. , Troxel Andrea , Feldman Michael , Lal Priti , Rosen Mark , Burrell Jessica , Redlinger Colleen , Gallagher Maryann , Bradbury Angela R. , Domchek Susan M. , Fox Kevin R. , O'Dwyer Peter J. , DeMichele Angela M.
Published: April 2023

Supplementary Figure 1: Trial Enrollment Schema Supplementary Figure 2: Kaplan Meier Curve Among Patients Receiving Palbociclib and Paclitaxel
Table S1 from The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis
Authors: Kim Jee-Youn , Jeon Seulgi , Yoo Young Jo , Jin Hee , Won Hee Yeon , Yoon Kyeonghee , Hwang Eun Sook , Lee Yoon-Jin , Na Younghwa , Cho Jaeho , Lee Yun-Sil
Published: April 2023

List of primers
Supplementary information from The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis
Authors: Kim Jee-Youn , Jeon Seulgi , Yoo Young Jo , Jin Hee , Won Hee Yeon , Yoon Kyeonghee , Hwang Eun Sook , Lee Yoon-Jin , Na Younghwa , Cho Jaeho , Lee Yun-Sil
Published: April 2023

Supplementary information
Supplementary Tables from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
Authors: Costa-Nunes Carla , Cachot Amélie , Bobisse Sara , Arnaud Marion , Genolet Raphael , Baumgaertner Petra , Speiser Daniel E. , Sousa Alves Pedro M. , Sandoval Federico , Adotévi Olivier , Reith Walter , Protti Maria Pia , Coukos George , Harari Alexandre , Romero Pedro , Jandus Camilla
Published: April 2023

Supplementary Tables
Supplementary Figures 1-8 from The Hsp27-Mediated IkBα-NFκB Signaling Axis Promotes Radiation-Induced Lung Fibrosis
Authors: Kim Jee-Youn , Jeon Seulgi , Yoo Young Jo , Jin Hee , Won Hee Yeon , Yoon Kyeonghee , Hwang Eun Sook , Lee Yoon-Jin , Na Younghwa , Cho Jaeho , Lee Yun-Sil
Published: April 2023

Supplementary Figures 1-8
Figure S6 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
Authors: Costa-Nunes Carla , Cachot Amélie , Bobisse Sara , Arnaud Marion , Genolet Raphael , Baumgaertner Petra , Speiser Daniel E. , Sousa Alves Pedro M. , Sandoval Federico , Adotévi Olivier , Reith Walter , Protti Maria Pia , Coukos George , Harari Alexandre , Romero Pedro , Jandus Camilla
Published: April 2023

Supplementary Figure 6
Figure S5 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
Authors: Costa-Nunes Carla , Cachot Amélie , Bobisse Sara , Arnaud Marion , Genolet Raphael , Baumgaertner Petra , Speiser Daniel E. , Sousa Alves Pedro M. , Sandoval Federico , Adotévi Olivier , Reith Walter , Protti Maria Pia , Coukos George , Harari Alexandre , Romero Pedro , Jandus Camilla
Published: April 2023

Supplementary Figure 5
Supplementary Figure 2 from Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial
Authors: Cox M. Christina , Castiello Luciano , Mattei Mauro , Santodonato Laura , D'Agostino Giuseppina , Muraro Elena , Martorelli Debora , Lapenta Caterina , Di Napoli Arianna , Di Landro Francesca , Cangemi Michela , Pavan Antonio , Castaldo Paolo , Hohaus Stefan , Donati Simona , Montefiore Enrica , Berdini Cinzia , Carlei Davide , Monque Domenica M. , Ruco Luigi , Prosperi Daniela , Tafuri Agostino , Spadaro Francesca , Sestili Paola , Spada Massimo , Dolcetti Riccardo , Santini Stefano M. , Rozera Carmela , Aricò Eleonora , Capone Imerio , Belardelli Filippo
Published: April 2023

CT-PET scan showing clinical response of Pt#3
Supplementary Figure 1 from Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial
Authors: Cox M. Christina , Castiello Luciano , Mattei Mauro , Santodonato Laura , D'Agostino Giuseppina , Muraro Elena , Martorelli Debora , Lapenta Caterina , Di Napoli Arianna , Di Landro Francesca , Cangemi Michela , Pavan Antonio , Castaldo Paolo , Hohaus Stefan , Donati Simona , Montefiore Enrica , Berdini Cinzia , Carlei Davide , Monque Domenica M. , Ruco Luigi , Prosperi Daniela , Tafuri Agostino , Spadaro Francesca , Sestili Paola , Spada Massimo , Dolcetti Riccardo , Santini Stefano M. , Rozera Carmela , Aricò Eleonora , Capone Imerio , Belardelli Filippo
Published: April 2023

CT-PET scan showing clinical response of Pt#2.
Figure S2 from High-throughput Screening of Human Tumor Antigen–specific CD4 T Cells, Including Neoantigen-reactive T Cells
Authors: Costa-Nunes Carla , Cachot Amélie , Bobisse Sara , Arnaud Marion , Genolet Raphael , Baumgaertner Petra , Speiser Daniel E. , Sousa Alves Pedro M. , Sandoval Federico , Adotévi Olivier , Reith Walter , Protti Maria Pia , Coukos George , Harari Alexandre , Romero Pedro , Jandus Camilla
Published: April 2023

Supplementary Figure 2
Supplementary Data from Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer
Authors: Blair Alex B. , Kim Victoria M. , Muth Stephen T. , Saung May Tun , Lokker Nathalie , Blouw Barbara , Armstrong Todd D. , Jaffee Elizabeth M. , Tsujikawa Takahiro , Coussens Lisa M. , He Jin , Burkhart Richard A. , Wolfgang Christopher L. , Zheng Lei
Published: April 2023

Supplemental Data: Figure S1: Pathologic representation of hemispleen liver metastases; Figure S2: Treatment schema; Figure S3: Supplemental survival; Figure S4: FACS PD1/PDL1 expression; Figure S5: Myeloid cell FACS; Figure S6: Multiplex IHC of myeloid cell and HA high/low; Figure S7: CXCR4 survival; Figure S8: Multiplex and RNAseq PD1/PDL1
Supplementary Table 1 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Patient characteristics per PD-L1 stratification subgroups
Supplementary Data from Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer
Authors: Fendler Wolfgang P. , Weber Manuel , Iravani Amir , Hofman Michael S. , Calais Jérémie , Czernin Johannes , Ilhan Harun , Saad Fred , Small Eric J. , Smith Matthew R. , Perez Paola M. , Hope Thomas A. , Rauscher Isabel , Londhe Anil , Lopez-Gitlitz Angela , Cheng Shinta , Maurer Tobias , Herrmann Ken , Eiber Matthias , Hadaschik Boris
Published: April 2023

Supplementary materials for Fendler et al.
Supplementary Figures from EPB41L5 Mediates TGFβ-Induced Metastasis of Gastric Cancer
Authors: Jeong Mi-Hyeon , Park Soo-Yeon , Lee Seung-Hyun , Seo JaeSung , Yoo Jung-Yoon , Park Seung-Ho , Kim Mi Jeong , Lee SooYeon , Jang Subhin , Choi Hyo-Kyoung , Lee Jae Eun , Shin Su-Jin , Choi Kyung-Chul , Cheong Jae-Ho , Yoon Ho-Geun
Published: April 2023

Supplementary Data_Clean
Supplementary Figure S1 from Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Saltos Andreas , Tanvetyanon Tawee , Haura Eric B. , Creelan Ben , Antonia Scott J. , Shafique Michael , Zheng Hong , Dai Wenjie , Saller James J. , Chen Zhihua , Tchekmedyian Nishan , Goas Kristen , Thapa Ram , Boyle Theresa A. , Chen Dung-Tsa , Beg Amer A.
Published: April 2023

Kaplan-Meier estimates of Progression-free survival (A) and Overall survival (B) in ICI refractory and relapsed patients.
Supplementary Data from Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma
Authors: Wong Pok Fai , Wei Wei , Smithy James W. , Acs Balazs , Toki Maria I. , Blenman Kim R.M. , Zelterman Daniel , Kluger Harriet M. , Rimm David L.
Published: April 2023

revised supplemental data
Supplementary Data 6 from Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms
Authors: Carrillo-Cruz Estrella , García-Lozano José R. , Márquez-Malaver Francisco J. , Sánchez-Guijo Fermín M. , Montero Cuadrado Isabel , Ferra i Coll Christelle , Valcárcel David , López-Godino Oriana , Cuesta Marian , Parody Rocío , López-Corral Lucía , Alcoceba Miguel , Caballero-Velázquez Teresa , Rodríguez-Gil Alfonso , Bejarano-García José A. , Ramos Teresa Lopes , Pérez-Simón José A.
Published: April 2023

Syntaxis for Cox model
Supplementary Data 1 from Vitamin D Modifies the Incidence of Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation Depending on the Vitamin D Receptor (VDR) Polymorphisms
Authors: Carrillo-Cruz Estrella , García-Lozano José R. , Márquez-Malaver Francisco J. , Sánchez-Guijo Fermín M. , Montero Cuadrado Isabel , Ferra i Coll Christelle , Valcárcel David , López-Godino Oriana , Cuesta Marian , Parody Rocío , López-Corral Lucía , Alcoceba Miguel , Caballero-Velázquez Teresa , Rodríguez-Gil Alfonso , Bejarano-García José A. , Ramos Teresa Lopes , Pérez-Simón José A.
Published: April 2023

Characteristics of the patients.
Supplementary Materials and Methods from IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3
Authors: Koh Jaemoon , Kim Hye Young , Lee Youngha , Park In Kyu , Kang Chang Hyun , Kim Young Tae , Kim Ji-Eun , Choi Murim , Lee Won-Woo , Jeon Yoon Kyung , Chung Doo Hyun
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure Legends from TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
Authors: Werbrouck Coralie , Evangelista Cláudia C.S. , Lobón-Iglesias María-Jesús , Barret Emilie , Le Teuff Gwénaël , Merlevede Jane , Brusini Romain , Kergrohen Thomas , Mondini Michele , Bolle Stéphanie , Varlet Pascale , Beccaria Kevin , Boddaert Nathalie , Puget Stéphanie , Grill Jacques , Debily Marie-Anne , Castel David
Published: April 2023

Supplementary Figure Legends
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Parada Carolina A. , Osbun Joshua W. , Busald Tina , Karasozen Yigit , Kaur Sumanpreet , Shi Min , Barber Jason , Adidharma Widya , Cimino Patrick J. , Pan Catherine , Gonzalez-Cuyar Luis F. , Rostomily Robert , Born Donald E. , Zhang Jing , Ferreira Manuel
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Parada Carolina A. , Osbun Joshua W. , Busald Tina , Karasozen Yigit , Kaur Sumanpreet , Shi Min , Barber Jason , Adidharma Widya , Cimino Patrick J. , Pan Catherine , Gonzalez-Cuyar Luis F. , Rostomily Robert , Born Donald E. , Zhang Jing , Ferreira Manuel
Published: April 2023

Figure S1
Supplementary Table S4 from BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas
Authors: Field Matthew G. , Kuznetsov Jeffim N. , Bussies Parker L. , Cai Louie Z. , Alawa Karam A. , Decatur Christina L. , Kurtenbach Stefan , Harbour J. William
Published: April 2023

HyperMethvsDecGE_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for hypermethylated/downregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HypoMethvsIncGE_ChrLoc: Chromosomal loci enriched (FDR < 0.05) for hypomethylated/upregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HyperMethvsDecGE_KEGG_REACTOME: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for hypermethylated/downregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HypoMethvsIncGE_KEGG_REACTOME: Functional (KEGG and REACTOME) pathways enriched (FDR < 0.05) for hypomethylated/upregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HyperMethvsDecGE_GO: Gene ontology molecular functions enriched (FDR < 0.05) for hypermethylated/downregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HypoMethvsIncGE_GO: Gene ontology molecular functions enriched (FDR < 0.05) for hypomethylated/upregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HyperMethvsDecGE_TF: Promoter region transcription factor binding sites enriched (FDR < 0.05) for hypermethylated/downregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas HypoMethvsIncGE_TF: Promoter region transcription factor binding sites enriched (FDR < 0.05) for hypomethylated/upregulated genes in Class 2 uveal melanomas compared to Class 1 uveal melanomas
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Authors: Parada Carolina A. , Osbun Joshua W. , Busald Tina , Karasozen Yigit , Kaur Sumanpreet , Shi Min , Barber Jason , Adidharma Widya , Cimino Patrick J. , Pan Catherine , Gonzalez-Cuyar Luis F. , Rostomily Robert , Born Donald E. , Zhang Jing , Ferreira Manuel
Published: April 2023

Table S8
Supplementary Table S4 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Table S4. miRNA expression, mRNA expression, and associated pathways perturbed in the GIST882 cell line after anagrelide treatment.
Supplementary Table S3 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Table S3. Comprehensive drug sensitivity and resistance testing with 200 cancer drugs. Cell viability in GIST882 and GIST48 cell lines was measured in five different concentrations over a 10,000-fold concentration range.
Supplementary Table 1 from Anagrelide for Gastrointestinal Stromal Tumor
Authors: Pulkka Olli-Pekka , Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Mpindi John-Patrick , Tynninen Olli , Icay Katherine , Cervera Alejandra , Keskitalo Salla , Murumägi Astrid , Kulesskiy Evgeny , Laaksonen Maria , Wennerberg Krister , Varjosalo Markku , Laakkonen Pirjo , Lehtonen Rainer , Hautaniemi Sampsa , Kallioniemi Olli , Schöffski Patrick , Sihto Harri , Joensuu Heikki
Published: April 2023

Supplementary Table S1. The outlier mRNA expression profiles of the gene tissue index (GTI) outlier analysis. The list of 2415 outlier genes in GIST is ranked by the gene tissue index.
Table S4 from Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach
Authors: Chang Jason C. , Alex Deepu , Bott Matthew , Tan Kay See , Seshan Venkatraman , Golden Andrew , Sauter Jennifer L. , Buonocore Darren J. , Vanderbilt Chad M. , Gupta Sounak , Desmeules Patrice , Bodd Francis M. , Riely Gregory J. , Rusch Valerie W. , Jones David R. , Arcila Maria E. , Travis William D. , Ladanyi Marc , Rekhtman Natasha
Published: April 2023

Supplemental Table 4
Figure S6 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Sensitivity of BRCA1-deficient RPE cells with acquired olaparib resistance to prexasertib and lack of effect of monotherapy pre-treatment on the synergistic cytotoxicity between prexasertib and olaparib in TOV112D cells
Figure S5 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Synergism of prexasertib and olaparib in ovarian cancer cell lines
Figure S4 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

Cyclin E expression in ovarian cancer cell lines
Figure S3 from The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
Authors: Parmar Kalindi , Kochupurakkal Bose S. , Lazaro Jean-Bernard , Wang Zhigang C. , Palakurthi Sangeetha , Kirschmeier Paul T. , Yang Chunyu , Sambel Larissa A. , Färkkilä Anniina , Reznichenko Elizaveta , Reavis Hunter D. , Dunn Connor E. , Zou Lee , Do Khanh T. , Konstantinopoulos Panagiotis A. , Matulonis Ursula A. , Liu Joyce F. , D'Andrea Alan D. , Shapiro Geoffrey I.
Published: April 2023

RAD51 and gamma-H2AX staining in response to olaparib in HGSOC PDX models
Supplementary Data from Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Authors: Colomban Olivier , Tod Michel , Leary Alexandra , Ray-Coquard Isabelle , Lortholary Alain , Hardy-Bessard Anne Claire , Pfisterer Jacobus , Du Bois Andreas , Kurzeder Christian , Burges Alexander , Péron Julien , Freyer Gilles , You Benoit
Published: April 2023

Table 1.Appendix. Characteristics of the patients included in the landmark survival analysis Table 2. Appendix. Typical parameter estimates from the final semi-mechanistic model in the learning set AGO-OVAR 9. Table 3.Appendix. Covariates associated with progression-free survival (PFS-months) in the 3 datasets Table 4. Appendix. Impact of KELIM terciles on PFS (progression-free survival) and OS (overall survival) adjusted on risk classes defined by Oza et al. in the ICON 7 trial. Table 5. Appendix. Predictive value of KELIM terciles and other prognostic factors regarding progression-free survival (PFS) and overall survival (OS) in univariate and multivariate models in every trial considered separately. Table 6.Appendix. Univariate Weibull accelerated failure time model regarding overall survival (OS) on the pooled datasets Figure 1. Appendix. Semi-mechanistic model. AMT is the amount of drug administered. C1 and C2 are the drug concentration in compartment 1 and 2 (Arbitrary Units). Figure 2.Appendix. Predictive value of KELIM and other prognostic factors regarding progression free survival (PFS, left panel) and overall survival (OS, right panel) assessed using C-index. Figure 3. Appendix. Goodness-of-fit plot for the AGO-OVAR 9 learning set. Predicted versus observed concentrations are shown for (left) the population and for (right) individuals. Black line: identity line. Figure 4. Appendix. Visual predictive checks for the 3 datasets. Figure 5. Appendix. Outcomes of overall survival analyses with KELIM adjusted for the treatment arms (ARM) for the three datasets (the learning set AGO-OVAR 9; the two validation sets AGO-OVAR7 and ICON-7). Figure 6. Appendix. Linear regression between overall survival hazard ratios and KELIM ratios in the 3 phase III trials.